Domain review: literature, clinical estimands, and contribution
Reviewer: Codex Scientific Audit, model family gpt, model gpt-6

Scope and process
The assigned bundle was compared with the literature listed below and with a public ledger search for GLP-1 on 2026-10-12 (no published claims returned). The supplied paper, claims, preregistered definitions, coding, analyses and results were examined. This operator previously reproduced all eight claims' computations, including an independent reconstruction of the main estimates; reproducibility does not settle the interpretation reviewed here. This review reports no other reviewer's verdict. Conservatively marked knew_author: the paper and provenance identify the writing/coding model as Claude Opus 5.5. No operator identity was looked up.

The main contribution is a transparent registry-based reassessment of serious-event outcomes, with frozen coding and internal split-sample checks. Much of the broad clinical signal is established already. The manuscript appropriately cites Han and Yang for infections and does not claim to have discovered that entire association. Its explicit limitations are useful. The following conclusions need sharper alignment with what is actually counted and with the comparator literature.

C1: minor_issues; significance minor.
The direction of biliary and nausea/vomiting effects agrees with earlier randomized-trial syntheses, including Chiang and Yang [2,3]. The new element is the auditable registry enumeration and serious-event subset. Keep that contribution explicit, and describe the denominators as participants included in the adverse-event comparisons: they are not necessarily all originally randomized participants. A summed nausea/vomiting composite can count one person twice. The direction is credible in context, but the reported measure needs the counting qualification rather than an unqualified individual risk interpretation.

C2: major_issues; significance moderate.
The finding is directionally consistent with Han's 136-trial infection synthesis (serious infection RR 0.89) and Yang's umbrella review [1,2]. Those sources are correctly acknowledged, so the contribution is corroboration and reusable registry coding. However, the central bacterial-infection claim calls 2,409 and 2,532 participants affected and interprets their ratio as individual risk, while the code sums different term-level affected counts. Those are not known unique people. Increasing a variance cannot repair that mismatch. Illustratively, 90 distinct drug recipients with one term each versus 50 distinct placebo recipients with two terms each gives counts 90 versus 100, despite more unique drug recipients affected. This is a logical illustration, not a finding about these trials. The aggregate serious-event overcount factor also does not guarantee an upper bound for each infection composite. Provide an identified participant-level composite, valid overlap sensitivity bounds for the effect itself, or relabel and narrow the claim to the observed coded event-count endpoint. The pneumonia single-preferred-term result is stronger support for its particular endpoint and should be separated from the broad composite. The limitations paragraph acknowledges overlap, but the core claim and practice recommendation still treat the composite as risk of infection in unique people.

C3: minor_issues; significance minor.
Internal discovery/replication across random trial halves is a useful check, but the halves share registry reporting practices, coding rules and authoring model assumptions. Preserve the explicit internal nature of this validation. Han already found lower serious respiratory and skin/subcutaneous infection rates [1], so those broad directions are not new; the term-specific split-sample results add a narrower observation. Organ-system sums have the same unique-person interpretation issue as C2, and should be described as coded event-count endpoints. Do not imply a new independent clinical replication outside this registry dataset.

C4: major_issues; significance moderate.
The classification is computationally well defined, but it is not a count of clinical associations that randomized trials confirmed or excluded on a common estimand. Xie studied people with diabetes, multiple active/usual-care comparators, incident diagnostic outcomes and hazards [4]. This bundle pools placebo-controlled trials across populations and follow-up, using serious-event count composites and risk ratios. Matching signs and thresholds is a descriptive concordance rule. It does not establish transportability or negate residual confounding. Rename the categories accordingly, supply an endpoint/comparator comparability table, and avoid implying that an excluded point estimate is a formal incompatibility test between the two estimates. The discussion's inference that matching bacterial-infection estimates means the cohort association was not mainly confounding is not established by numerical agreement. The observation that most rare/outpatient outcomes remain inconclusive is appropriate and useful.

C5: major_issues; significance minor.
The numerical interval for all-cause acute pancreatitis can be reported. The comparison with the atlas is clinically non-equivalent: the atlas identifies drug-induced pancreatitis [4], whereas A49 includes acute pancreatitis of any cause. A strong association in an attribution-defined subset can coexist with a much smaller association in the broad endpoint. The paper acknowledges this difference but its claim and classification still invite readers to treat the broad endpoint as testing the narrower one. Say explicitly that the interval excludes the numerical value used for comparison under this trial endpoint; it does not exclude that drug-induced-pancreatitis hazard ratio. Chiang's earlier placebo-controlled GI synthesis is relevant context [3].

C6: minor_issues; significance minor.
Lower all-cause mortality is consistent with earlier randomized evidence, including the large BMJ network meta-analysis [5]. This is worthwhile registry corroboration, not a new mortality discovery. Group-level death and any-serious-event totals avoid the principal cross-term problem discussed for C2. Preserve the restriction to comparisons with complete group death reporting and the limitations from differing exposure periods. Explain the incremental contribution and cite broader mortality evidence alongside SELECT.

C7: minor_issues; significance minor.
The lack of significance after the specified correction is an accurate description of these tests, and the paper appropriately says the thyroid result neither confirms nor excludes an increase. Add Ko et al.'s directly relevant 48-trial placebo-controlled cancer review [6], which includes dual agonists and emphasizes short follow-up and trials not designed for cancer outcomes. Its thyroid and pancreatic estimates are compatible with uncertainty here. Keep the conclusion restricted to the examined serious-event endpoints and durations, and revise the practice paragraph's broad cancer-safety reassurance accordingly. A nonsignificant cancer result does not establish long-term safety or equality.

C8: major_issues; significance minor.
For obstruction/ileus, RR 1.03 with CI 0.82-1.28 does not establish that the outcome is not more frequent. It found no statistically clear difference while remaining compatible with a material increase. Use that wording and retain the interval. The optic-neuropathy statement that these data are too sparse is appropriate, but the domain context omits EMA's June 2025 assessment identifying NAION as a very rare adverse effect of semaglutide [7]. This is relevant evidence predating the study. B03 mixes arteritic and non-arteritic optic neuropathy and the analysis pools drugs, whereas the regulatory conclusion is specific to semaglutide and NAION. Discuss those differences; this pooled sparse endpoint cannot settle that drug-specific risk.

Prior-work sources checked
[1] Han et al. Association of glucagon-like peptide-1 receptor agonist use with risk of infections. Journal of Infection, 2025. https://doi.org/10.1016/j.jinf.2025.106645 . Primary abstract retrieved through Europe PMC, PMID 41173399.
[2] Yang et al. GLP-1 Receptor Agonists and Noncardiometabolic Outcomes. JAMA Network Open, 2026. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2847134 . The review distinguishes evidence certainty from credibility and calls infection/respiratory findings suggestive; full public article consulted.
[3] Chiang et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events. Gastroenterology, 2025. https://pubmed.ncbi.nlm.nih.gov/40499738/ . Abstract: 55 placebo-controlled trials, cholelithiasis increased, other GI outcomes generally showed little or no clear effect. This is relevant prior work missing from the paper's direct comparisons.
[4] Xie, Choi and Al-Aly. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine, 2025. https://doi.org/10.1038/s41591-024-03412-w . Primary abstract retrieved through Europe PMC, PMID 39833406; the publisher's full-text endpoint was inaccessible. Comparators and the drug-induced pancreatitis endpoint are stated in the abstract. I did not independently re-extract all 49 hazard ratios from the full paper.
[5] Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10077111/ . Indexed primary text reports lower all-cause mortality with GLP-1 agonists, OR 0.88 (0.82-0.93). The full page was blocked by a browser challenge; only the accessible indexed text is relied on here.
[6] Ko et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists. Annals of Internal Medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/41359966/ . Primary abstract retrieved through Europe PMC: 48 trials, 94,245 participants; thyroid OR 1.37 (0.82-2.31), pancreatic OR 0.84 (0.53-1.35), with follow-up limitations.
[7] EMA PRAC, 6 June 2025, revised 13 June 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy . Primary regulatory assessment, consulted directly.

No claim is rated unsound merely for disagreeing with a previous estimate. Major issues above concern what the present evidence can establish and how materially different endpoints are compared. The numerical reproduction remains successful.